403 related articles for article (PubMed ID: 30245692)
1. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
Front Immunol; 2018; 9():2034. PubMed ID: 30245692
[No Abstract] [Full Text] [Related]
2. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
[TBL] [Abstract][Full Text] [Related]
3. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.
Ohno Y; Kitamura H; Takahashi N; Ohtake J; Kaneumi S; Sumida K; Homma S; Kawamura H; Minagawa N; Shibasaki S; Taketomi A
Cancer Immunol Immunother; 2016 Feb; 65(2):193-204. PubMed ID: 26759006
[TBL] [Abstract][Full Text] [Related]
4. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
[No Abstract] [Full Text] [Related]
5. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
6. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
7. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
8. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.
Yuan J; Kashiwagi S; Reeves P; Nezivar J; Yang Y; Arrifin NH; Nguyen M; Jean-Mary G; Tong X; Uppal P; Korochkina S; Forbes B; Chen T; Righi E; Bronson R; Chen H; Orsulic S; Brauns T; Leblanc P; Scholler N; Dranoff G; Gelfand J; Poznansky MC
J Hematol Oncol; 2014 Feb; 7():15. PubMed ID: 24565018
[TBL] [Abstract][Full Text] [Related]
9. In vitro interactions between gamma deltaT cells, DC, and CD4+ T cells; implications for the immunotherapy of leukemia.
Ye Z; Haley S; Gee AP; Henslee-Downey PJ; Lamb LS
Cytotherapy; 2002; 4(3):293-304. PubMed ID: 12194726
[TBL] [Abstract][Full Text] [Related]
10. Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
Marcq E; Audenaerde JRV; Waele J; Jacobs J; Loenhout JV; Cavents G; Pauwels P; Meerbeeck JPV; Smits EL
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31455014
[TBL] [Abstract][Full Text] [Related]
11. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
12. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
13. Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.
McDonnell AM; Cook A; Robinson BWS; Lake RA; Nowak AK
BMC Cancer; 2017 Jun; 17(1):417. PubMed ID: 28619093
[TBL] [Abstract][Full Text] [Related]
14. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
[TBL] [Abstract][Full Text] [Related]
15. Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
Cornelissen R; Hegmans JP; Maat AP; Kaijen-Lambers ME; Bezemer K; Hendriks RW; Hoogsteden HC; Aerts JG
Am J Respir Crit Care Med; 2016 May; 193(9):1023-31. PubMed ID: 26652184
[TBL] [Abstract][Full Text] [Related]
16. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
18. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory molecules in patients with gestational diabetes mellitus.
Pendeloski KP; Mattar R; Torloni MR; Gomes CP; Alexandre SM; Daher S
Endocrine; 2015 Sep; 50(1):99-109. PubMed ID: 25754913
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]